Vor Biopharma Inc. (VOR) P/E Ratio History
Insufficient DataInsufficient historical P/E data to classify valuation. · Data 2026–2026
Loading P/E history...
P/E Ratio Analysis
As of June 12, 2026, Vor Biopharma Inc. (VOR) trades at a price-to-earnings ratio of -0.2x, with a stock price of $14.09 and trailing twelve-month earnings per share of $-2053.13.
Compared to the Healthcare sector median P/E of 23.1x, VOR trades at a 101% discount to its sector peers. The sector includes 235 companies with P/E ratios ranging from 0.0x to 187.5x.
Relative to the broader market, VOR trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our VOR DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
VOR Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
VOR P/E vs Peers
Cell and Gene Therapy Developers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $25B | 30.5Lowest | 7.21Best | +171%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
What if you invested $1,000 in VOR back in 2026?
Total return with dividends reinvested · 0+ years of data
Calculate ReturnsHow much would $100/month in VOR be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs VOR Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationVOR vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowVOR — Frequently Asked Questions
Quick answers to the most common questions about buying VOR stock.
What is VOR's P/E ratio?
Vor Biopharma Inc. (VOR) trailing twelve-month P/E ratio is -0.2x, based on TTM diluted EPS of $-2053.13. The 5-year average P/E is N/A and the historical range spans N/A to N/A.
Is VOR stock overvalued or undervalued?
VOR current P/E: -0.2x. 5-year average P/E: N/A. Percentile: N/A.
Is VOR stock expensive?
VOR is fairly valued relative to its own history. The current P/E of -0.2x is near the 5-year average of N/A (N/A percentile of historical range).
What is VOR's historical P/E range?
Over the past 5 years, VOR's P/E ratio has ranged from N/A to N/A, with a median of N/A and an average of N/A. The current P/E of -0.2x places the stock at the N/A percentile of this range. Full historical data spans 2026–2026.
How does VOR's P/E compare to the S&P 500?
VOR trades at -0.2x P/E versus the S&P 500 median of 24.9x. The 101% discount to the market suggests lower growth expectations or perceived higher risk.
How does VOR's valuation compare to Healthcare peers?
Vor Biopharma Inc. P/E of -0.2x compares to the Healthcare sector median of 23.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is VOR's PEG ratio?
VOR PEG ratio is N/A, based on a P/E of -0.2x and EPS growth of -107.4%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is VOR's earnings yield?
VOR earnings yield is N/A, the inverse of its -0.2x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.